August 27, 2022, Revolution Cancer International Molecular Tumor Board -GSK, SMARCA4, MTAP, NSCLC

Поделиться
HTML-код
  • Опубликовано: 19 ноя 2024

Комментарии • 1

  • @revolutioncancer6610
    @revolutioncancer6610  2 года назад

    Please note the niraparib breast cancer trial was done in patients who are BRCA 1/2 mutated. We should have made that more clear when talking about it. We apologize for the confusion.